Pfizer manufactures tofacitinib [1]. The drug is marketed under the brand name Xeljanz [1].
What is Tofacitinib used for?
Tofacitinib is a Janus kinase (JAK) inhibitor used to treat moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis [1]. It is also indicated for polyarticular course of juvenile idiopathic arthritis in patients 2 years of age and older [1].
When does Tofacitinib's patent expire?
Patent expiry dates for drugs like tofacitinib can vary due to multiple patents covering different aspects of the drug, formulation, and manufacturing processes. Information on specific patent expiries and potential challenges can be found on DrugPatentWatch.com [2].
What are the risks associated with Tofacitinib?
Tofacitinib carries a boxed warning regarding the risk of serious infections, mortality, major adverse cardiovascular events, and thrombosis [1]. Other serious side effects include blood clots in the lungs and deep veins, stroke, heart attack, cancer, and allergic reactions [1].
Are there other JAK inhibitors available?
Yes, other JAK inhibitors are available, including baricitinib (Olumiant), upadacitinib (Rinvoq), and filgotinib (Jyseleca) [3]. These drugs work similarly by inhibiting JAK enzymes but may differ in their specific targets and approved indications [3].